PAUL Glaucoma Implant

Surgical Technique

Paul Implantation Technique by
Prof. Keith Barton2

Surgical Videos

Play Video
Play Video
Play Video
Play Video
Play Video
Play Video
Play Video
Play Video
Play Video
Play Video

Clinical Data

In a multi-center clinical study, a 62% reduction in IOP was observed 12 months after surgery. Similarly, glaucoma medications needed was reduced from 3.3 to 0.3 post-operatively*

Koh V, Chew P, Triolo G, et al. Treatment outcome using the PAUL glaucoma implant to control intraocular pressure in eye with refractory glaucoma. Ophthalmol Glaucoma. 2020;3:350-9.

1 Koh V, Chew P, Triolo G, et al. Treatment outcomes using the PAUL glaucoma implant to control intraocular pressure in eyes with refractory glaucoma. Ophthalmol Glaucoma. 2020;3:350-9.

2 Heuer DK, Barton K, Grehn F, et al. Consensus on definitions of success. In: Shaarawy TM, Sherwood MB, Grehn F, editors. Guidelines on Design and Reporting of Surgical Trials. World Glaucoma Association; 2008. p. 15-24.

Significant reductions in both IOP and Glaucoma medications used were observed after one year implanting of PAUL®.

The failure rate was 5%, the complete success rate was 69% and the qualified success rate was 93%.

INTERESTED IN FINDING OUT MORE OR
WISH TO COLLABORATE?​